登录

Shenzhi Technology Closes ¥100M Series B Financing, Developing AI-Based Ultrasonic Products

作者: Mailman 2021-01-26 16:49
深至科技
https://www.weicha88.com/
企业数据由 动脉橙 提供支持
AI超声影像研发商 | C+轮 | 运营中
中国-上海
2023-04-07
成为资本
查看

(VCBeat) Jan. 23, 2021-- Recently, AI company Shanghai Shenzhi Information Technology Co., Ltd. ("Shenzhi Technology") announced the closing of a Series B round worth 100 million RMB led by GGV Capital.


Shenzhi Technology was incubated by portable diagnostic ultrasound medical equipment provider Stork Healthcare and formally established in 2018. The company focuses on intelligent diagnosis and AI applications with ultrasound and has formed more than 10 kinds of image databases covering over 30 diseases. Shenzhi Technology has also built a cloud-based ultrasound imaging center. Its AI-based ultrasound products have covered diseases of thyroid, breast, liver, carotid plaque, pelvic floor, orthopedics, and neurology.


In 2020, Shenzhi Technology raised three rounds of financing totally from investors including ZheShang Venture Capital, Shun Yi Capital, Health 100, etc. According to Zhu Ruixing, CEO of Shenzhi Technology, the fresh round of funding will be used to develop ultrasonic products and accelerate commercialization.


The emergence of AI provides a solution for the problem of the popularization of ultrasonic products. On the one hand, AI can make large ultrasonic equipment smarter and become an intelligent terminal integrating data collection, management and analysis, and deep learning. On the other hand, AI can lower the threshold for the use of ultrasound, so that more non-professional doctors can learn how to use the equipment, and "examination" is an essential process to solve the structural contradictions of diagnostics and treatment.


At present, the products of Shenzhi Technology have served more than 600 hospitals from the first-class hospitals at third grade to primary hospitals, building a mature business network. The next goal of Shenzhi Technology is to get the approval of class III devices and realize the transformation from launch to commercialization.


>>>>

About GGV Capital


GGV Capital is a global venture capital firm that invests in local founders. As a multi-stage, sector-focused firm, GGV focuses on seed-to-growth stage investments across Consumer/New Retail, Social/Digital & Internet, Enterprise/Cloud and Frontier Tech sectors. The firm was founded in 2000 and manages $6.2 billion in capital across 13 funds.

相关赛道 医疗信息化
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

引领超声影像技术无极探索,迈瑞医疗的AI之路正结出累累硕果

行业大咖共话脊柱侧弯筛诊治一体化体系构建模式,三维肌骨超声无辐射解决方案矩阵助力产业发展

《2022数字医疗年度创新白皮书》发布,三大领域五大热点全面讲述数字医疗“中国故事”

高容科技:软硬件并进研发,填补国内肿瘤穿刺介入手术机器人空白

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Westlake Therapeutics Secures ¥100 Million in Series Pre-A+ Funding

2021-01-26
下一篇

全年超400条政策解析医改7大关键词,探明医疗政策制定与实施走向 | 2020年度盘点

2021-01-27